Dr Reddys Laboratories (RDY) Cash from Investing Activities (2024 - 2025)

Dr Reddys Laboratories (RDY) recorded quarterly Cash from Investing Activities of -$109.4 million in Q3 2025, up 51.21% quarter-over-quarter from -$224.3 million in Q2 2025, and up 51.95% on a YoY basis from -$72.0 million in Q3 2024.

Dr Reddys Laboratories (RDY) Cash from Investing Activities (2024 - 2025) Analysis & Trends

Dr Reddys Laboratories' Cash from Investing Activities history runs 2 years deep, the most recent figure standing at -$109.4 million for Q3 2025.

  • In Q3 2025, Cash from Investing Activities rose 51.95% year-over-year to -$109.4 million; the TTM figure through Sep 2025 stood at -$804.1 million (changed N/A YoY), while the FY2026 annual figure was -$700.0 million, down 2.64% from the prior year.
  • Cash from Investing Activities was -$109.4 million for Q3 2025 at Dr Reddys Laboratories, up from -$224.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$109.4 million in Q3 2025 to a low of -$242.7 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 229.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -87.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 743.70 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -506.20 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -60.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -2.08 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -15.45 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 25.99 Mn
10 Dr Reddys Laboratories 122.03 Mn -51.98 Mn 368.55 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 -109.41 Mn
Sep 30, 2025 -109.41 Mn
Jun 30, 2025 -224.25 Mn
Jun 30, 2025 -224.25 Mn
Sep 30, 2024 -227.70 Mn
Sep 30, 2024 -227.70 Mn
Jun 30, 2024 -242.73 Mn
Jun 30, 2024 -242.73 Mn